<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="/wp-content/plugins/xml-sitemap-feed/assets/sitemap-news.xsl?ver=5.7.7"?>
<!-- generated-on="2026-07-16T21:42:53+00:00" -->
<!-- generator="XML Sitemap & Google News for WordPress" -->
<!-- generator-url="https://status301.net/wordpress-plugins/xml-sitemap-feed/" -->
<!-- generator-version="5.7.7" -->
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" >
<url><loc>https://diabeticinsieme.it/farmaci-obesita-rimborso-consumi-semaglutide/</loc><news:news><news:publication><news:name>Diabetic Insieme</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-07-15T05:45:33+02:00</news:publication_date><news:title>Farmaci contro l&#8217;obesità, il nodo del rimborso mentre i consumi di semaglutide crescono</news:title></news:news></url>
<url><loc>https://diabeticinsieme.it/dblg2-diabeloop-pancreas-artificiale-app-fda/</loc><news:news><news:publication><news:name>Diabetic Insieme</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-07-15T05:45:19+02:00</news:publication_date><news:title>DBLG2, il pancreas artificiale via app di Diabeloop ottiene il via libera della FDA</news:title></news:news></url>
<url><loc>https://diabeticinsieme.it/vitamina-d-diabete-tipo-2-profilo-genetico-prevenzione/</loc><news:news><news:publication><news:name>Diabetic Insieme</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-07-15T05:44:38+02:00</news:publication_date><news:title>Vitamina D e diabete, uno studio lega l&#8217;effetto protettivo al profilo genetico</news:title></news:news></url>
<url><loc>https://diabeticinsieme.it/immunostem-padova-terapia-genica-cellulare-diabete-tipo-1/</loc><news:news><news:publication><news:name>Diabetic Insieme</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-07-15T05:44:23+02:00</news:publication_date><news:title>Immunostem, a Padova il primo studio italiano di terapia genica e cellulare per il diabete di tipo 1</news:title></news:news></url>
</urlset>
